P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS. (23rd June 2022) - Kulasekararaj, A.; Brodsky, R.; Griffin, M.; Kulagin, A.; Ogawa, M.; Wang, J.; Mujeebuddin, A.; Nishimura, J.-I.; Peffault de Latour, R.; Szer, J.; Lee, J. W.